KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Cash from Operations (2017 - 2025)

Bionano Genomics' Cash from Operations history spans 7 years, with the latest figure at 5870000.0 for Q3 2025.

  • For Q3 2025, Cash from Operations rose 55.89% year-over-year to 5870000.0; the TTM value through Sep 2025 reached 18652000.0, up 79.77%, while the annual FY2024 figure was 68900000.0, 44.96% up from the prior year.
  • Cash from Operations for Q3 2025 was 5870000.0 at Bionano Genomics, down from 3500000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 2800000.0 in Q1 2025 and bottomed at 36696000.0 in Q2 2023.
  • The 5-year median for Cash from Operations is 25622000.0 (2021), against an average of 21210210.53.
  • The largest annual shift saw Cash from Operations crashed 133.7% in 2022 before it skyrocketed 90.05% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 25622000.0 in 2021, then plummeted by 34.72% to 34517000.0 in 2022, then increased by 13.73% to 29779000.0 in 2023, then surged by 78.23% to 6482000.0 in 2024, then grew by 9.44% to 5870000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Cash from Operations are 5870000.0 (Q3 2025), 3500000.0 (Q2 2025), and 2800000.0 (Q1 2025).